MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-KR-03-0046142
Hemogenomics Private Limited - healthcare in Bangalore, Karnataka, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹102.89 Cr
▲ 3% YoY
Net profit · FY 2025
₹7.08 Cr
Net margin 6.9%
EBITDA · FY 2025
₹12.65 Cr
EBITDA margin 12.3%
Authorised capital
₹4 Cr
Registered with MCA
Paid-up capital
₹2.23 Cr
Issued & subscribed
Open charges
₹68.54 Cr
Secured borrowings
Company age
24 yrs
Est. 2002
Employees · EPFO
99
Provident fund records
About Hemogenomics Private Limited
Data last updated:
Hemogenomics Private Limited is a private limited company based in Bangalore, Karnataka, India. It operates in the diagnostic centers and pathology labs segment of the healthcare sector. It was incorporated on 22 January 2002 and has been in existence for over 24 years.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U73100KA2002PTC030032. Its GSTIN is 29AABCH0743B1Z2 (Karnataka). The company holds 10 GST registrations, of which 6 are active.
The company has an authorised share capital of ₹4 Cr and a paid-up capital of ₹2.23 Cr. It is led by directors including Sumit Bagaria (Managing Director) and William J Rutter.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Bangalore, Karnataka.
As per the financials filed for FY 2025, the company reported a revenue of ₹102.89 Cr, a growth of 3% compared to the previous year. For the same year it recorded a net profit of ₹7.08 Cr (net margin 6.9%) and EBITDA of ₹12.65 Cr (EBITDA margin 12.3%). Revenue has grown at a compounded annual rate (CAGR) of 13% over three years and 10% over five years.
The company has about 99 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Hemogenomics. As per MCA filings, the company has open charges of ₹68.54 Cr on record. Court records list 48 cases involving the company, including 38 filed by the company and 10 filed against it; 6 cases are pending. The company has 5 deals on record (3 secondary share transfers, 1 funding round, 1 rights issue), with disclosed funding of ₹1.93 Cr; the latest was in March 2021.
Hemogenomics Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-KR-03-0046142). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website hemogenomics.com.
Company details
CIN U73100KA2002PTC030032
Registration Number 030032
Incorporation Date 22 January 2002
ROC Bangalore
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-KR-03-0046142
Recognitions & Rankings of Hemogenomics
Contact details
Hemogenomics Private Limited's registered office is in Bangalore, Karnataka. Its website is hemogenomics.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address3rd Floor Site No. 26 (Opp. Indian Oil Petrol Bunk), New Bel Road M.S. Ramaiah, Bangalore, Karnataka, India – 560054
- IndustryHealthcare, Diagnostic Centers & Pathology Labs
To see the full contact details of Hemogenomics Private Limited, buy the company report.
Comprehensive company report
Hemogenomics Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Hemogenomics operates one associated brand: Hemogenomics. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Provider of blood screening technology for the early detection of diseases | hemogenomics.com |
Business activity
The main business activities of Hemogenomics are trade and hospital and medical care. In detail, this covers wholesale trading and other hospital and medical care activities. 2 activity segments are registered with the MCA.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | |
| Q | Hospital and Medical Care | Q6 | Other Hospital and Medical Care Activities |
To see the full business activity and turnover split of Hemogenomics Private Limited, buy the company report.
Financials of Hemogenomics Private Limited
FY 2025 filings availableHemogenomics Private Limited reported revenue of ₹102.89 Cr (up 3% YoY) for FY 2025.
Revenue · FY 2025
₹102.89 Cr ▲ 3%
Net profit · FY 2025
₹7.08 Cr margin 6.9%
EBITDA · FY 2025
₹12.65 Cr margin 12.3%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 3%
3 years · compounded
▲ 13%
5 years · compounded
▲ 10%
EBITDA CAGR growth
3 years · compounded
▲ 60%
5 years · compounded
▲ 22%
Revenue has grown at a compounded annual rate (CAGR) of 10% over five years, including 3% growth in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹102.89 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹12.65 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹7.08 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 12.3% | ||||
| Net Profit Margin | 6.9% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Hemogenomics Private Limited, buy the company report.
Board of directors of Hemogenomics Private Limited
Hemogenomics has 4 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| William J Rutter | Director | 25 Nov 2002 | 23 Years 10 Months | Current |
| Anurag Bagaria | Director | 08 Mar 2010 | 16 Years 7 Months | Current |
| Sumit Bagaria | Managing Director | 18 Jan 2011 | 15 Years 9 Months | Current |
| Francisco Jose Dopazo Gonzalez | Director | 10 Jan 2025 | 1 Years 9 Months | Current |
Auditor
Hemogenomics Private Limited is audited by Guru and Jana for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Guru and Jana | FY 2023 | AABFA5265A |
Shareholding
The shareholding of Hemogenomics Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Hemogenomics Private Limited, buy the company report.
Charges & borrowings
Open charges
₹68.54 Cr
Satisfied charges
None
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 28 Jun 2025 | 101118743 | The Hongkong and Shanghai Banking Corporation Limited | ₹27.5 Cr | Open | |
| 20 Feb 2025 | 101080855 | Others | ₹1.04 Cr | Open | |
| 02 Mar 2016 | 100019339 | Citi Bank N.A. | ₹5 Cr | Open | |
| 11 Jan 2012 | 10337103 | Citi Bank N.A. | ₹35 Cr | Open |
To see the full charge records of Hemogenomics Private Limited, buy the company report.
Total charge records: 4 View all charges
Deals & funding
Hemogenomics Private Limited has 5 deals on record (3 secondary share transfers, 1 funding round, 1 rights issue), with disclosed funding of ₹1.93 Cr; the latest was in March 2021.
Total deals
5
Secondary share transfers
3
Funding round
1
Rights issue
1
Disclosed funding
₹1.93 Cr
Deals on record (5 of 5)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2021 | Secondary share transfer | Undisclosed | Buyer: Kemwell Private Limited Seller: Rubtech Exports Private Limited |
| Mar 2016 | Rights issue | ₹29.1 Lakh | Investors: an individual |
| Mar 2016 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: 2 individuals |
| Aug 2008 | Funding round | ₹1.93 Cr | Investors: Synergenics LLC, Rubtech Exports Private Limited , 2 individuals |
| Mar 2008 | Secondary share transfer | Undisclosed | Buyer: Rubtech Exports Private Limited Seller: an individual |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Hemogenomics Private Limited has 48 court cases on record: 38 filed by Hemogenomics, 10 filed against it. 6 cases are pending and 42 are disposed.
Total cases
48
Filed by the company
38
Filed against the company
10
Pending
6
Disposed
42
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 23 | 8 | 5 |
| District courts | 22 | 0 | 0 |
| Supreme Court | 3 | 2 | 1 |
Cases on record (5 of 48)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Rajasthan | Court case (SAW) | Filed by the company against Rajasthan Medical Services Corporation Limited, D-Block, Swasthya Bhawan, Tilak Marg, C-Scheme, Ja and 2 others | Pending |
| High Court, MAHARASHTRA | Writ petition | Filed against the company by Roche Diagnostics India Pvt. Ltd., Mumbai | Disposed |
| High Court, JAMMU & KASHMIR | Writ petition | Filed by the company against M/S Roche Diagnostics India Pvt. Ltd and 3 others | Disposed |
| High Court, ANDHRAPRADESH | Writ petition | Filed by the company against Roche Diagnostics India Private Limited 501B and 3 others | Disposed |
| High Court of Kerala | Appeal | Filed against the company by Kochin Inlab Equipments India Pvt. Ltd. | Disposed |
To see the full case history of Hemogenomics Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Hemogenomics Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Group structure & subsidiaries
Hemogenomics has 1 associated company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
1
Associated companies
Employees & EPFO
Hemogenomics Private Limited has a workforce of 99 employees on its EPFO records as of Apr 09, 2024, across 1 active EPFO establishment.
Employee count
99
Active EPFO establishments
1
Employee growth
-15.38%
GST
Hemogenomics has 10 GST registrations: 6 active and 4 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
10
Active
6
Cancelled / inactive
4
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AABCH0743B1Z2 | Karnataka | Active | 01 Jul 2017 |
| 06AABCH0743B1ZA | Haryana | Active | 01 Jul 2017 |
| 07AABCH0743B1Z8 | Delhi | Active | 01 Jul 2017 |
| 20AABCH0743B1ZK | Jharkhand | Active | 06 Feb 2021 |
To see the full GST registrations and return filing status of Hemogenomics Private Limited, buy the company report.
Recent activity
Hemogenomics Private Limited has 7 board changes on record since 2002: 4 appointments and 3 cessations. The latest: Francisco Jose Dopazo Gonzalez was appointed as Director on 10 Jan 2025.
AGM
Hemogenomics Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Charges
A charge with The Hongkong And Shanghai Banking Corporation Limited amounted to Rs. 27.50 Cr with Charge ID 101118743 was registered on 28 Jun 2025.
Filing
Hemogenomics Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Bangalore.
Charges
A charge with Others amounted to Rs. 1.04 Cr with Charge ID 101080855 was registered on 20 Feb 2025.
Appointed
Francisco Jose Dopazo Gonzalez was appointed as Director.
Charges
A charge with Citi Bank N.A. of Rs. 35.00 Cr registered on 11 Jan 2012 with Charge ID 10337103 was modified on 15 Feb 2022.
Charges
A charge with Citi Bank N.A. amounted to Rs. 5.00 Cr with Charge ID 100019339 was registered on 02 Mar 2016.
Ceased
Narayanan Vaghul ceased to be Director.
Charges
A charge with Citi Bank N.A. amounted to Rs. 35.00 Cr with Charge ID 10337103 was registered on 11 Jan 2012.
Appointed
Sumit Bagaria was appointed as Managing Director.
Ceased
Ashok Sekhar Ganguly ceased to be Director.
Ceased
Subhash Bagaria ceased to be Nominee Director.
3 earlier events are in the company report.
Frequently asked questions
Hemogenomics is an active private limited company based in Bangalore, Karnataka, India. The company works in diagnostic centers and pathology labs, within the healthcare industry. It was incorporated on 22 January 2002 (24+ years old) and is registered under CIN U73100KA2002PTC030032.
Hemogenomics has 4 current directors:
- Sumit Bagaria - Managing Director
- William J Rutter - Director
- Anurag Bagaria - Director
- Francisco Jose Dopazo Gonzalez - Director
The latest financial statements of Hemogenomics on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Hemogenomics is 29AABCH0743B1Z2, registered in Karnataka. The company has 10 GST registrations in all, of which 6 are active and 4 are cancelled or inactive. Other active GSTINs include 06AABCH0743B1ZA (Haryana), 07AABCH0743B1Z8 (Delhi), 20AABCH0743B1ZK (Jharkhand).
The CIN (Corporate Identification Number) of Hemogenomics is U73100KA2002PTC030032. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Hemogenomics has 48 court cases on record: 38 filed by the company and 10 filed against it. 6 are pending. Most are in the high courts.
Hemogenomics was incorporated on 22 January 2002, making it 24+ years old. It is registered with the Registrar of Companies, Bangalore.
Hemogenomics has 5 deals on record (3 secondary share transfers, 1 funding round, 1 rights issue), with disclosed funding of ₹1.93 Cr; the latest was in March 2021.
Francisco Jose Dopazo Gonzalez was appointed as Director on 10 Jan 2025. Narayanan Vaghul ceased to be Director on 07 Apr 2015. Sumit Bagaria was appointed as Managing Director on 18 Jan 2011. Hemogenomics has 7 board changes on record in total.
Yes, Hemogenomics is registered as a medium enterprise under Udyam registration (number: UDYAM-KR-03-0046142).